Ulcerative colitis Digestive System Ulcerative colitis
Conditions
Interventions
People were allocated randomly at the hospital to the control or intervention group by lottery until occupying the places of the group.
The study consists of two periods: a wash-out p
Sponsors
Institute of Food Science Research
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients diagnosed with mild or moderate ulcerative colitis
Exclusion criteria
Exclusion criteria: 1. Antibiotic intake up to 6 months before the study 3. Type I diabetes, endocrine and gastrointestinal disorders 4. Addiction to drugs or alcohol 5. Restrictive diets (vegetarians, vegans)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Markers of ulcerative colitis such as fecal calprotectin, iron, ferritin, C-reactive protein and white and blood cells measured by routine blood tests at initial and end treatment point (4 weeks) | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Quality of life measured by quality of life questionnaires (IBDQ-32) at initial and end treatment point (4 weeks) 2. Microbial phenolic metabolites in faeces and urine measured by ultra-high-performance liquid chromatography–electrospray ionization–?tandem mass spectrometry (UHPLC-ESI-MS/MS) at initial and end treatment point (4 weeks) 3. Short and medium-chain fatty acids in faeces measured by solid-phase microextraction gas chromatography-mass spectrometry (SPME-GC-MS) at initial and end treatment point (4 weeks) 4. Composition, abundance and diversity of the faecal microbiota measured by sequencing the V3-V4 region of ribosomal DNA from fecal samples and metagenomic analysis at initial and end treatment point (4 weeks) | — |
Countries
Spain
Outcome results
None listed